In this preclinical study, we directly compared the activity of the XPO1 inhibitor selinexor and doxorubicin, the standard front-line medical therapy in sarcomas, on in-house developed DDLPS PDXs and corresponding cell lines. Here, XPO1 is linked to sarcoma.